Encorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E/K Positive Melanoma

NCT04657991

Last updated date
Study Location
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female participants ≥ 18 years at the time of informed consent.

- Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

- Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition.

- Presence of at least 1 measurable lesion as detected by radiological and/or photographic methods according to RECIST v1.1.

- ECOG performance status 0 or 1.

- Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-based local laboratory assay (eg, US FDA-approved test, CE-marked [European conformity] in vitro diagnostic in EU countries, or equivalent), obtained during the course of normal clinical care, in a CLIA- or similarly certified laboratory.

- Submission of adequate tumor tissue (archival or newly obtained; block or slides to the sponsor central laboratory(ies) during the screening period and prior to enrollment (SLI)/randomization (Phase 3).

- Have not received prior first-line systemic therapy for metastatic or unresectable locally advanced melanoma.

- Adequate bone marrow function, hepatic and renal function.

- Capable of giving signed informed consent.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Other medical or psychiatric condition including recent (within the past year) or
active suicidal ideation/behavior or laboratory abnormality that may increase the risk
of study participation or, in the investigator's judgment, make the participant
inappropriate for the study.


- Mucosal or ocular melanoma.


- Diagnosis of immunodeficiency or an active autoimmune disease that required systemic
treatment in the past 2 years (ie, with use of disease modifying agents,
corticosteroids, or immunosuppressive drugs).


- Clinically significant multiple or severe drug allergies, intolerance to topical
corticosteroids, or severe post-treatment hypersensitivity reactions (including, but
not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal
necrolysis, and exfoliative dermatitis).


- Unable to swallow, retain, and absorb oral medications.


- Impairment of GI function or disease which may significantly alter the absorption of
oral study intervention (eg, uncontrolled nausea, vomiting or diarrhea, malabsorption
syndrome, including malabsorption syndrome secondary to prior GI surgery).


- Clinically significant cardiovascular diseases,


- History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to enrollment
(SLI)/randomization (Phase 3). Examples include transient ischemic attacks,
cerebrovascular accidents, hemodynamically significant (ie, massive or sub-massive)
deep vein thrombosis or pulmonary emboli.


- History or current evidence of RVO or current risk factors for RVO (eg, uncontrolled
glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability
syndromes); history of retinal degenerative disease.


- Concurrent neuromuscular disorder that is associated with the potential of elevated CK
(eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis,
spinal muscular atrophy).


- Current noninfectious pneumonitis or history of noninfectious pneumonitis requiring
steroids.


- Evidence of HBV or HCV infection.


- Known history of a positive test for HIV or known AIDS.


- Any active infection requiring systemic therapeutic treatment within 2 weeks prior to
enrollment (SLI)/ randomization (Phase 3).


- Participants with prior or current symptomatic brain metastasis, leptomeningeal
disease or other active CNS metastases.


- Concurrent or previous other malignancy within 2 years of study entry, except
curatively treated basal or squamous cell skin cancer, prostate intraepithelial
neoplasm, carcinoma in-situ of the cervix, Bowen's disease and Gleason ≤ 6 prostate
cancer. Participants with a history of other curatively treated cancers must be
reviewed with the sponsor or designee prior to entering the study.


- Participants who previously received and subsequently discontinued encorafenib and/or
binimetinib and/or anti-PD-1/-L1 due to severe toxicity.


- For participants in the SLI only: Current use or anticipated need for food or drugs
that are known moderate or strong CYP3A4 inhibitors during screening and through the
DLT-evaluation period


- Participant has not recovered to Grade ≤ 1 from toxic effects of prior therapy and/or
complications from prior surgical intervention before enrollment (SLI)/ randomization
(Phase 3).


- Receipt of protocol defined medications or treatments outside of required intervals
before enrollment (SLI)/randomization (Phase 3):


- Previous administration with an investigational drug ≤ 6 months prior to enrollment
(SLI)/randomization (Phase 3).


- Known sensitivity or contraindication to any component of study intervention
(encorafenib, binimetinib and pembrolizumab), or their excipients.


- Pregnant, confirmed by a positive β-hCG laboratory test result, or is breastfeeding
(lactating).


- Investigator site staff or Pfizer employees directly involved in the conduct of the
study, site staff otherwise supervised by the investigator, and their respective
family members.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

MelanomaEncorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E/K Positive Melanoma
NCT04657991
  1. Westwood, Kansas
  2. Tucson, Arizona
  3. Tucson, Arizona
  4. Tucson, Arizona
  5. Aventura, Florida
  6. Cape Coral, Florida
  7. Fort Myers, Florida
  8. Orlando, Florida
  9. Orlando, Florida
  10. Orlando, Florida
  11. Billings, Montana
  12. Billings, Montana
  13. Cincinnati, Ohio
  14. West Chester, Ohio
  15. Knoxville, Tennessee
  16. Nashville, Tennessee
  17. Nashville, Tennessee
  18. Temple, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
NCT01909453
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Fayetteville, Arkansas
  6. Rogers, Arkansas
  7. Orange County, California
  8. Orange, California
  9. Orange, California
  10. Orange, California
  11. Aurora, Colorado
  12. Boulder, Colorado
  13. Colorado Springs, Colorado
  14. Denver, Colorado
  15. Lakewood, Colorado
  16. Parker, Colorado
  17. Pueblo, Colorado
  18. Chicago, Illinois
  19. Chicago, Illinois
  20. Chicago, Illinois
  21. Chicago, Illinois
  22. Chicago, Illinois
  23. Goshen, Indiana
  24. Goshen, Indiana
  25. Grand Rapids, Michigan
  26. Grand Rapids, Michigan
  27. Jackson, Mississippi
  28. Jackson, Mississippi
  29. Hackensack, New Jersey
  30. Rochester, New York
  31. Rochester, New York
  32. Dallas, Texas
  33. Dallas, Texas
  34. Burlington, Vermont
  35. Burlington, Vermont
  36. Burlington, Vermont
  37. Alexandria, Virginia
  38. Arlington, Virginia
  39. Fairfax, Virginia
  40. Fairfax, Virginia
  41. Fairfax, Virginia
  42. Fairfax, Virginia
  43. Fairfax, Virginia
  44. Falls Church, Virginia
  45. Gainesville, Virginia
  46. Leesburg, Virginia
  47. Leesburg, Virginia
  48. Woodbridge, Virginia
  49. Wenatchee, Washington
  50. Caba, Buenos Aires
  51. Buenos Aires, Ciudad Autónoma DE Buenosaires
  52. Buenos Aires, Ciudad Autónoma DE Buenosaires
  53. Buenos Aires, Ciudad Autónoma DE Buenosaires
  54. Buenos Aires, Ciudad Autónoma DE Buenosaires
  55. Buenos Aires, Ciudad Autónoma DE Buenosaires
  56. Buenos Aires, Ciudad Autónoma DE Buenosaires
  57. Gateshead, New South Wales
  58. Southport, Queensland
  59. Southport, Queensland
  60. Southport, Queensland
  61. Woolloongabba, Queensland
  62. Melbourne, Victoria
  63. Prahran, Victoria
  64. Nedlands, Western Australia
  65. Recife, Pernambuco
  66. Ijuí, RIO Grande DO SUL
  67. Porto Alegre, RIO Grande DO SUL
  68. Barretos, SAO Paulo
  69. Natal,
  70. Rio de Janeiro,
  71. Sao Paulo,
  72. Calgary, Alberta
  73. Toronto, Ontario
  74. Toronto, Ontario
  75. Toronto, Ontario
  76. Montreal, Quebec
  77. Montreal, Quebec
  78. Montreal, Quebec
  79. Montreal, Quebec
  80. Québec, Quebec
  81. Bogotá, Distrito Capital DE Bogotá
  82. Bogotá, Pbx (57-1)
  83. Brno, Jihomoravský KRAJ
  84. Praha 10, Praha, Hlavní Mesto
  85. Praha 2, Praha, Hlavní Mesto
  86. Brno,
  87. Olomouc,
  88. Ostrava Poruba,
  89. Praha,
  90. Nice, Alpes-maritimes
  91. Bordeaux, Gironde
  92. Grenoble, Isère
  93. Reims, Marne
  94. Lille, Nord
  95. Lyon, Rhone
  96. Lyon, Rhône
  97. Le Mans, Sarthe
  98. Villejuif, Val-de-marne
  99. Boulogne-Billancourt,
  100. Lille,
  101. Lyon,
  102. Nice,
  103. Paris,
  104. Paris,
  105. Paris,
  106. Paris,
  107. Pierre-bénite,
  108. Strasbourg,
  109. Templemars,
  110. Villejuif,
  111. Freiburg im Breisgau, Baden-württemberg
  112. Heidelberg, Baden-württemberg
  113. Mannheim, Baden-württemberg
  114. Tübingen, Baden-württemberg
  115. Ulm, Baden-württemberg
  116. München, Bayern
  117. Regensburg, Bayern
  118. Regensburg, Bayern
  119. Würzburg, Bayern
  120. Frankfurt, Hessen
  121. Kassel, Hessen
  122. Kassel, Hessen
  123. Buxtehude, Niedersachsen
  124. Buxtehude, Niedersachsen
  125. Bonn, Nordrhein-westfalen
  126. Minden, Nordrhein-westfalen
  127. Minden, Nordrhein-westfalen
  128. Mainz, Rheinland-pfalz
  129. Magdeburg, Sachsen-anhalt
  130. Dresden, Sachsen
  131. Leipzig, Sachsen
  132. Berlin, Schleswig-holstein
  133. Luebeck, Schleswig-holstein
  134. Lübeck, Schleswig-holstein
  135. Berlin,
  136. Bonn,
  137. Bonn,
  138. Dresden,
  139. Dresden,
  140. Erfurt,
  141. Erfurt,
  142. Essen,
  143. Freiburg,
  144. Gera,
  145. Gera,
  146. Gera,
  147. Hamburg,
  148. Hannover,
  149. Hannover,
  150. Hannover,
  151. Heidelberg,
  152. Homburg,
  153. Kiel,
  154. Lübeck,
  155. Magdeburg,
  156. Magdeburg,
  157. Mainz,
  158. Mannheim,
  159. Minden,
  160. Münster,
  161. Nürnberg,
  162. Regensburg,
  163. Tübingen,
  164. Ulm,
  165. Ulm,
  166. Athens, Attiki
  167. Athens,
  168. Athens,
  169. Piraeus,
  170. Debrecen, Hajdú-bihar
  171. Budapest,
  172. Budapest,
  173. Szolnok,
  174. Ramat Gan, Tel-aviv
  175. Haifa,
  176. Jerusalem,
  177. Torrette Site, Ancona
  178. Napoli, Campania
  179. Roma, Lazio
  180. Roma, Lazio
  181. Roma, Lazio
  182. Roma, Lazio
  183. Lecco, Lombardia
  184. Milan, Lombardia
  185. Monza, Lombardia
  186. Rozzano, Lombardia
  187. Rozzano, Lombardia
  188. Candiolo, Torino
  189. Pisa, Toscana
  190. Terni, Umbria
  191. Padua, Veneto
  192. Bari,
  193. Bergamo,
  194. Bologna,
  195. Genoa,
  196. Milano,
  197. Napoli,
  198. Padova,
  199. Pavia,
  200. Ragusa,
  201. Rome,
  202. Siena,
  203. Torino,
  204. Udine,
  205. Fukuoka-shi, Fukuoka
  206. Matsumoto, Nagano
  207. Chuo-ku, Tokyo
  208. Niigata,
  209. Osaka, Ôsaka
  210. Gangnam-Gu, Seoul Teugbyeolsi
  211. Songpa-Gu, Seoul Teugbyeolsi
  212. Seoul,
  213. Seoul,
  214. Seoul,
  215. Seoul,
  216. Mexico,
  217. Mexico,
  218. Nijmegen, Gelderland
  219. Heerlen, Limburg
  220. Amsterdam, Noord Holland
  221. Breda, Noord-brabant
  222. Eindhoven, Noord-brabant
  223. Veldhoven, Noord-brabant
  224. Enschede, Overijssel
  225. Zwolle, Overijssel
  226. Groningen,
  227. Leiden,
  228. Maastricht,
  229. Rotterdam,
  230. Rotterdam,
  231. Sittard-Geleen,
  232. Oslo,
  233. Oslo,
  234. Oslo,
  235. Warsaw, Mazowieckie
  236. Warszawa, Mazowieckie
  237. Warszawa,
  238. Lisbon, Lisboa
  239. Porto, Proto
  240. Almada,
  241. Lisboa,
  242. Lisboa,
  243. Lisboa,
  244. Porto,
  245. Moscow,
  246. Ryazan',
  247. Ryazan,
  248. Ryazan,
  249. St. Petersburg,
  250. Singapore,
  251. Singapore,
  252. Singapore,
  253. Bratislava,
  254. Bratislava,
  255. Bratislava,
  256. Poprad,
  257. Pretoria,
  258. Pretoria,
  259. Jerez De La Frontera, Andalucía
  260. Oviedo, Asturias
  261. Barcelona, Cataluña
  262. El Palmar, Murcia
  263. Pamplona, Navarra
  264. Pamplona, Navarra
  265. Alicante,
  266. Badalona,
  267. Barcelona,
  268. Barcelona,
  269. Barcelona,
  270. Barcelona,
  271. Donostia-san Sebastián,
  272. Dos Hermanas,
  273. Granada,
  274. La Coruna,
  275. Lleida,
  276. Lleida,
  277. Madrid,
  278. Madrid,
  279. Madrid,
  280. Madrid,
  281. Majadahonda,
  282. Malaga,
  283. Sevilla,
  284. Sevilla,
  285. Sevilla,
  286. Valencia,
  287. Gavle,
  288. Göteborg,
  289. Lund,
  290. Solna,
  291. Uppsala,
  292. Zurich, Zürich (DE)
  293. Bern,
  294. Zürich,
  295. Zürich,
  296. Zürich,
  297. Bornova,
  298. Izmir,
  299. Izmir,
  300. Cambridge, Cambridgeshire
  301. Preston, Lancashire
  302. London, London, CITY OF
  303. Guildford, Surrey
  304. Bebington, Wirral
  305. Sheffield, York
  306. Broomfield,
  307. Leeds,
  308. London,
  309. Manchester,
  310. Oxford,
  311. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
NCT03159117
  1. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPhase I Oncovir Poly IC:LC and NY-ESO-1/gp100
NCT01008527
  1. Tampa, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Encorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E/K Positive Melanoma
Official Title  ICMJE A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Metastatic OR Unresectable Locally Advanced Melanoma
Brief Summary This is a randomized, double-blind, placebo-controlled, Phase 3 study to compare the efficacy, safety, and tolerability of encorafenib and binimetinib plus pembrolizumab (Triplet Arm) versus placebo plus pembrolizumab (Control Arm) in participants with metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma.
Detailed Description This is a randomized, double-blind, placebo-controlled, Phase 3 study to compare the efficacy, safety, and tolerability of encorafenib and binimetinib plus pembrolizumab (Triplet Arm) versus placebo plus pembrolizumab (Control Arm) in participants with metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma. The study will have an open-label safety lead-in (SLI) phase to determine the safety recommended phase 3 dose (RP3D) and pharmacokinetics (PK) of encorafenib and binimetinib plus pembrolizumab combination therapy prior to initiation of the randomized Phase 3 part of the study. Two dose levels of encorafenib in combination with binimetinib plus pembrolizumab will be explored in parallel. A minimum of 12 evaluable participants will be enrolled per dose level. During the double-blind randomized Phase 3 part of the study, approximately 600 eligible participants will be randomized in a 1:1 ratio to the Triplet Arm (at RP3D determined in the SLI) or Control Arm (approximately 300 participants per arm). Randomization will be stratified by prior systemic adjuvant therapy and stage of disease by AJCC (ED8)
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Melanoma
Intervention  ICMJE
  • Drug: Encorafenib
    Encorafenib
    Other Name: BRAFTOVI
  • Drug: Binimetinib
    Binimetinib
    Other Name: MEKTOVI
  • Drug: Pembrolizumab
    Pembrolizumab
    Other Name: KEYTRUDA
Study Arms  ICMJE
  • Experimental: Triplet Arm
    Encorafenib and Binimetinib in combination with Pembrolizumab
    Interventions:
    • Drug: Encorafenib
    • Drug: Binimetinib
    • Drug: Pembrolizumab
  • Active Comparator: Control Arm
    Pembrolizumab
    Intervention: Drug: Pembrolizumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 1, 2020)
624
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 8, 2030
Estimated Primary Completion Date January 10, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female participants ? 18 years at the time of informed consent.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition.
  • Presence of at least 1 measurable lesion as detected by radiological and/or photographic methods according to RECIST v1.1.
  • ECOG performance status 0 or 1.
  • Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-based local laboratory assay (eg, US FDA-approved test, CE-marked [European conformity] in vitro diagnostic in EU countries, or equivalent), obtained during the course of normal clinical care, in a CLIA- or similarly certified laboratory.
  • Submission of adequate tumor tissue (archival or newly obtained; block or slides to the sponsor central laboratory(ies) during the screening period and prior to enrollment (SLI)/randomization (Phase 3).
  • Have not received prior first-line systemic therapy for metastatic or unresectable locally advanced melanoma.
  • Adequate bone marrow function, hepatic and renal function.
  • Capable of giving signed informed consent.

Exclusion Criteria

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Mucosal or ocular melanoma.
  • Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
  • Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
  • Unable to swallow, retain, and absorb oral medications.
  • Impairment of GI function or disease which may significantly alter the absorption of oral study intervention (eg, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, including malabsorption syndrome secondary to prior GI surgery).
  • Clinically significant cardiovascular diseases,
  • History of thromboembolic or cerebrovascular events ? 12 weeks prior to enrollment (SLI)/randomization (Phase 3). Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (ie, massive or sub-massive) deep vein thrombosis or pulmonary emboli.
  • History or current evidence of RVO or current risk factors for RVO (eg, uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes); history of retinal degenerative disease.
  • Concurrent neuromuscular disorder that is associated with the potential of elevated CK (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
  • Current noninfectious pneumonitis or history of noninfectious pneumonitis requiring steroids.
  • Evidence of HBV or HCV infection.
  • Known history of a positive test for HIV or known AIDS.
  • Any active infection requiring systemic therapeutic treatment within 2 weeks prior to enrollment (SLI)/ randomization (Phase 3).
  • Participants with prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases.
  • Concurrent or previous other malignancy within 2 years of study entry, except curatively treated basal or squamous cell skin cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, Bowen's disease and Gleason ? 6 prostate cancer. Participants with a history of other curatively treated cancers must be reviewed with the sponsor or designee prior to entering the study.
  • Participants who previously received and subsequently discontinued encorafenib and/or binimetinib and/or anti-PD-1/-L1 due to severe toxicity.
  • For participants in the SLI only: Current use or anticipated need for food or drugs that are known moderate or strong CYP3A4 inhibitors during screening and through the DLT-evaluation period
  • Participant has not recovered to Grade ? 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before enrollment (SLI)/ randomization (Phase 3).
  • Receipt of protocol defined medications or treatments outside of required intervals before enrollment (SLI)/randomization (Phase 3):
  • Previous administration with an investigational drug ? 6 months prior to enrollment (SLI)/randomization (Phase 3).
  • Known sensitivity or contraindication to any component of study intervention (encorafenib, binimetinib and pembrolizumab), or their excipients.
  • Pregnant, confirmed by a positive ?-hCG laboratory test result, or is breastfeeding (lactating).
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04657991
Other Study ID Numbers  ICMJE C4221016
STARBOARD ( Other Identifier: Alias Study Number )
2020-004850-31 ( EudraCT Number )
KEYNOTE-B80 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Merck Sharp & Dohme Corp.
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP